Hepatitis B in chronic kidney disease: moving toward effective prevention.
Control of hepatitis B virus (HBV) infection has been a continuous challenge in the management of patients with advanced kidney disease. HBV infections are still difficult to treat, so the main objective is disease prevention by timely immunization with hepatitis B surface antigen vaccines. In the general population, a simple two- or three-standard-dose vaccination strategy has been proven to be highly successful. In contrast, an intensified and more tailored approach is evolving in patients with advanced renal failure.
Unger
J K
JK
Department of Experimental Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany. juliane.unger@charite.de
Peters
H
H
D002908:Chronic Disease; D006509:Hepatitis B / Q000209:etiology* / Q000517:prevention & control*; D017325:Hepatitis B Vaccines; D006801:Humans; D007674:Kidney Diseases / Q000150:complications*
D017325:Hepatitis B Vaccines